Status:

COMPLETED

EPOMI Study: ErythroPOietin in Myocardial Infarction

Lead Sponsor:

University Hospital, Angers

Collaborating Sponsors:

Fédération Française de Cardiologie

Société Française de Cardiologie

Conditions:

Myocardial Infarction

Eligibility:

All Genders

18+ years

Phase:

PHASE2

Brief Summary

EPOMI is a randomized, open-label, parallel phase II clinical study that will evaluate the effects of a single erythropoietin administration on infarct size and cardiac remodeling in patients with acu...

Eligibility Criteria

Inclusion

  • ST-Segment elevation myocardial infarction \<6h
  • Infarct related artery : proximal circumflex artery , proximal and mid left anterior descending artery, 1st segment of the right coronary artery
  • TIMI 0 or 1 before angioplasty
  • Successful PCI defined by residual stenosis \< 50% and TIMI 2 or 3 flow grade
  • Body weight : \[50-110\] kg
  • Informed, written consent

Exclusion

  • Age \< 18
  • Pregnant, or parturient or breast-feeding women;
  • Sexually active women without efficient contraception;
  • Inability to fully cooperate with the study protocol
  • Pre-treatment with fibrinolysis ;
  • Previous Q-wave myocardial infarction or previous aorto-coronary bypass;
  • History of deep vein thrombosis or pulmonary embolism;
  • Contraindication to aspirin or clopidogrel ;
  • Cardiogenic shock ;
  • Cardiac resuscitated before angioplasty ;
  • Past or active erythropoietin therapy;
  • Contraindications to erythropoietin therapy: uncontrolled hypertension, known hypersensitivity to benzoic acid, chronic liver insufficiency, hemoglobin\> 16g / l, thrombocytosis, refractory anemia with excess of blasts;
  • Renal insufficiency (creatinine clearance \<30ml/mn.);
  • Active Malignancies
  • Any contraindications to magnetic resonance imaging: pacemaker and automatic cardiac defibrillator, hearing aid, neurostimulator, infusion pump etc metallic splinters in the eye, ferromagnetic haemostatic clips in the central nervous system cochlear implants, claustrophobia;
  • Allergy to gadolinium ;
  • Patient refusal / patient not having provided written informed consent.

Key Trial Info

Start Date :

April 1 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2010

Estimated Enrollment :

110 Patients enrolled

Trial Details

Trial ID

NCT00648089

Start Date

April 1 2008

End Date

December 1 2010

Last Update

January 31 2011

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

CHU Angers

Angers, France, 49933

2

Fabrice PRUNIER, MD, PhD,

Angers, France, 49933